Use of antiarrhythmic drugs in elderly patients

Hon Chi Lee, Kristin T L Huang, Win Kuang Shen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Human aging is a global issue with important implications for current and future incidence and prevalence of health conditions and disability. Cardiac arrhythmias, including atrial fibrillation, sudden cardiac death, and bradycardia requiring pacemaker placement, all increase exponentially after the age of 60. It is important to distinguish between the normal, physiological consequences of aging on cardiac electrophysiology and the abnormal, pathological alterations. The age-related cardiac changes include ventricular hypertrophy, senile amyloidosis, cardiac valvular degenerative changes and annular calcification, fibrous infiltration of the conduction system, and loss of natural pacemaker cells and these changes could have a profound effect on the development of arrhythmias. The age-related cardiac electrophysiological changes include up- and down-regulation of specific ion channel expression and intracellular Ca2+ overload which promote the development of cardiac arrhythmias. As ion channels are the substrates of antiarrhythmic drugs, it follows that the pharmacokinetics and pharmacodynamics of these drugs will also change with age. Aging alters the absorption, distribution, metabolism, and elimination of antiarrhythmic drugs, so liver and kidney function must be monitored to avoid potential adverse drug effects, and antiarrhythmic dosing may need to be adjusted for age. Elderly patients are also more susceptible to the side effects of many antiarrhythmics, including bradycardia, orthostatic hypotension, urinary retention, and falls. Moreover, the choice of antiarrhythmic drugs in the elderly patient is frequently complicated by the presence of co-morbid conditions and by polypharmacy, and the astute physician must pay careful attention to potential drug-drug interactions. Finally, it is important to remember that the use of antiarrhythmic drugs in elderly patients must be individualized and tailored to each patient's physiology, disease processes, and medication regimen.

Original languageEnglish (US)
Pages (from-to)184-194
Number of pages11
JournalJournal of Geriatric Cardiology
Volume8
Issue number3
DOIs
StatePublished - 2011

Fingerprint

Anti-Arrhythmia Agents
Cardiac Arrhythmias
Bradycardia
Ion Channels
Cardiac Electrophysiology
Polypharmacy
Orthostatic Hypotension
Urinary Retention
Sudden Cardiac Death
Amyloidosis
Drug Interactions
Pharmaceutical Preparations
Atrial Fibrillation
Hypertrophy
Up-Regulation
Down-Regulation
Pharmacokinetics
Physicians
Kidney
Liver

Keywords

  • Aging
  • Antiarrhythmic drugs
  • Cardiac electrophysiology
  • Ion channels
  • Pharmacodynamics
  • Pharmacokinetics
  • Polypharmacy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Geriatrics and Gerontology

Cite this

Use of antiarrhythmic drugs in elderly patients. / Lee, Hon Chi; Huang, Kristin T L; Shen, Win Kuang.

In: Journal of Geriatric Cardiology, Vol. 8, No. 3, 2011, p. 184-194.

Research output: Contribution to journalArticle

Lee, Hon Chi ; Huang, Kristin T L ; Shen, Win Kuang. / Use of antiarrhythmic drugs in elderly patients. In: Journal of Geriatric Cardiology. 2011 ; Vol. 8, No. 3. pp. 184-194.
@article{b5a7efa8f7db447882e4da0d8764aebf,
title = "Use of antiarrhythmic drugs in elderly patients",
abstract = "Human aging is a global issue with important implications for current and future incidence and prevalence of health conditions and disability. Cardiac arrhythmias, including atrial fibrillation, sudden cardiac death, and bradycardia requiring pacemaker placement, all increase exponentially after the age of 60. It is important to distinguish between the normal, physiological consequences of aging on cardiac electrophysiology and the abnormal, pathological alterations. The age-related cardiac changes include ventricular hypertrophy, senile amyloidosis, cardiac valvular degenerative changes and annular calcification, fibrous infiltration of the conduction system, and loss of natural pacemaker cells and these changes could have a profound effect on the development of arrhythmias. The age-related cardiac electrophysiological changes include up- and down-regulation of specific ion channel expression and intracellular Ca2+ overload which promote the development of cardiac arrhythmias. As ion channels are the substrates of antiarrhythmic drugs, it follows that the pharmacokinetics and pharmacodynamics of these drugs will also change with age. Aging alters the absorption, distribution, metabolism, and elimination of antiarrhythmic drugs, so liver and kidney function must be monitored to avoid potential adverse drug effects, and antiarrhythmic dosing may need to be adjusted for age. Elderly patients are also more susceptible to the side effects of many antiarrhythmics, including bradycardia, orthostatic hypotension, urinary retention, and falls. Moreover, the choice of antiarrhythmic drugs in the elderly patient is frequently complicated by the presence of co-morbid conditions and by polypharmacy, and the astute physician must pay careful attention to potential drug-drug interactions. Finally, it is important to remember that the use of antiarrhythmic drugs in elderly patients must be individualized and tailored to each patient's physiology, disease processes, and medication regimen.",
keywords = "Aging, Antiarrhythmic drugs, Cardiac electrophysiology, Ion channels, Pharmacodynamics, Pharmacokinetics, Polypharmacy",
author = "Lee, {Hon Chi} and Huang, {Kristin T L} and Shen, {Win Kuang}",
year = "2011",
doi = "10.3724/SP.J.1263.2011.00184",
language = "English (US)",
volume = "8",
pages = "184--194",
journal = "Journal of Geriatric Cardiology",
issn = "1671-5411",
publisher = "Institute of Geriatric Cardiology",
number = "3",

}

TY - JOUR

T1 - Use of antiarrhythmic drugs in elderly patients

AU - Lee, Hon Chi

AU - Huang, Kristin T L

AU - Shen, Win Kuang

PY - 2011

Y1 - 2011

N2 - Human aging is a global issue with important implications for current and future incidence and prevalence of health conditions and disability. Cardiac arrhythmias, including atrial fibrillation, sudden cardiac death, and bradycardia requiring pacemaker placement, all increase exponentially after the age of 60. It is important to distinguish between the normal, physiological consequences of aging on cardiac electrophysiology and the abnormal, pathological alterations. The age-related cardiac changes include ventricular hypertrophy, senile amyloidosis, cardiac valvular degenerative changes and annular calcification, fibrous infiltration of the conduction system, and loss of natural pacemaker cells and these changes could have a profound effect on the development of arrhythmias. The age-related cardiac electrophysiological changes include up- and down-regulation of specific ion channel expression and intracellular Ca2+ overload which promote the development of cardiac arrhythmias. As ion channels are the substrates of antiarrhythmic drugs, it follows that the pharmacokinetics and pharmacodynamics of these drugs will also change with age. Aging alters the absorption, distribution, metabolism, and elimination of antiarrhythmic drugs, so liver and kidney function must be monitored to avoid potential adverse drug effects, and antiarrhythmic dosing may need to be adjusted for age. Elderly patients are also more susceptible to the side effects of many antiarrhythmics, including bradycardia, orthostatic hypotension, urinary retention, and falls. Moreover, the choice of antiarrhythmic drugs in the elderly patient is frequently complicated by the presence of co-morbid conditions and by polypharmacy, and the astute physician must pay careful attention to potential drug-drug interactions. Finally, it is important to remember that the use of antiarrhythmic drugs in elderly patients must be individualized and tailored to each patient's physiology, disease processes, and medication regimen.

AB - Human aging is a global issue with important implications for current and future incidence and prevalence of health conditions and disability. Cardiac arrhythmias, including atrial fibrillation, sudden cardiac death, and bradycardia requiring pacemaker placement, all increase exponentially after the age of 60. It is important to distinguish between the normal, physiological consequences of aging on cardiac electrophysiology and the abnormal, pathological alterations. The age-related cardiac changes include ventricular hypertrophy, senile amyloidosis, cardiac valvular degenerative changes and annular calcification, fibrous infiltration of the conduction system, and loss of natural pacemaker cells and these changes could have a profound effect on the development of arrhythmias. The age-related cardiac electrophysiological changes include up- and down-regulation of specific ion channel expression and intracellular Ca2+ overload which promote the development of cardiac arrhythmias. As ion channels are the substrates of antiarrhythmic drugs, it follows that the pharmacokinetics and pharmacodynamics of these drugs will also change with age. Aging alters the absorption, distribution, metabolism, and elimination of antiarrhythmic drugs, so liver and kidney function must be monitored to avoid potential adverse drug effects, and antiarrhythmic dosing may need to be adjusted for age. Elderly patients are also more susceptible to the side effects of many antiarrhythmics, including bradycardia, orthostatic hypotension, urinary retention, and falls. Moreover, the choice of antiarrhythmic drugs in the elderly patient is frequently complicated by the presence of co-morbid conditions and by polypharmacy, and the astute physician must pay careful attention to potential drug-drug interactions. Finally, it is important to remember that the use of antiarrhythmic drugs in elderly patients must be individualized and tailored to each patient's physiology, disease processes, and medication regimen.

KW - Aging

KW - Antiarrhythmic drugs

KW - Cardiac electrophysiology

KW - Ion channels

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Polypharmacy

UR - http://www.scopus.com/inward/record.url?scp=80053532113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053532113&partnerID=8YFLogxK

U2 - 10.3724/SP.J.1263.2011.00184

DO - 10.3724/SP.J.1263.2011.00184

M3 - Article

C2 - 22783304

AN - SCOPUS:80053532113

VL - 8

SP - 184

EP - 194

JO - Journal of Geriatric Cardiology

JF - Journal of Geriatric Cardiology

SN - 1671-5411

IS - 3

ER -